{"nct_id":"NCT02252042","title":"Pembrolizumab (MK-3475) Versus Standard Treatment for Recurrent or Metastatic Head and Neck Cancer (MK-3475-040/KEYNOTE-040)","status":"COMPLETED","status_verified_date":"2023-06","start_date":"2014-11-17","start_date_type":"ACTUAL","primary_completion_date":"2017-05-15","primary_completion_date_type":"ACTUAL","completion_date":"2022-08-15","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["MRK"]}